AbbVie (NY: ABBV )
136.87 +3.43 (+2.57%) Official Closing Price Updated: 7:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Press Releases about AbbVie
Investors have had to digest some negative news headlines, but if you look past that a dividend king like JNJ can be a boring but reliable buy in this market
Johnson & Johnson: Taking The Bull By The Horns?
February 21, 2023
Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions.
Exposures Intellectual Property Legal Regulatory
AbbVie Has a Mixed Outlook After Mixed Earnings
February 13, 2023
AbbVie stock was up after posting a mixed fourth-quarter earnings report, but with the company's patent expiring on Humira, the stock is a hold
Topics Earnings Intellectual Property
Exposures Financial Intellectual Property
AbbVie Stock: Dividend King ABBV Overview
January 19, 2023
One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID
November 17, 2022
Palm Beach, FL – November 17, 2022 – FinancialNewsMedia.com News Commentary – Since the beginning of the pandemic, the critical effort of researchers is to understand how coronavirus damages the body....
Can AbbVie Grow Revenue When Humira Biosimilars Hit The Market?
November 16, 2022
Shares of AbbVie have been in rally mode since late October. The company has newer drugs whose revenue could make up for declines due to Humira's patent expiry.
AbbVie Inc (NYSE:ABBV) AbbVie Inc (NYSE:ABBV) quarterly sales were below Wall Street’s expectations on Friday, primarily due to lower-than-anticipated income from its popular cosmetic filler Juvederm...
Exposures Economy Interest Rates
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following